BiotechTube

Lorcaserin hydrochloride + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cardiovascular Disease

Conditions

Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes

Trial Timeline

Jan 24, 2014 → May 14, 2018

NCT ID
NCT02019264

About Lorcaserin hydrochloride + Placebo

Lorcaserin hydrochloride + Placebo is a approved stage product being developed by Eisai for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02019264. Target conditions include Cardiovascular Disease, High Cardiovascular Risk, Obesity.

What happened to similar drugs?

20 of 20 similar drugs in Cardiovascular Disease were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅Empagliflozin + PlacebosEli LillyApproved
✅Aspirin + Placebo + ticagrelorAstraZenecaApproved
✅Rosuvastatin Oral TabletAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02019264ApprovedCompleted

Competing Products

20 competing products in Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
Midazolam + AZD5718AstraZenecaPhase 1
29